Affordable Access

Access to the full text

An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

Authors
  • Chou, Cheng-Wei1, 2
  • Huang, Yu-Kai1
  • Kuo, Ting-Ting
  • Liu, Jing-Pei1
  • Sher, Yuh-Pyng1, 3
  • 1 (J.-P.L.)
  • 2 Department of Medicine, Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 407, Taiwan
  • 3 Chinese Medicine Research Center, China Medical University, Taichung 404, Taiwan
Type
Published Article
Journal
International Journal of Molecular Sciences
Publisher
MDPI AG
Publication Date
Oct 21, 2020
Volume
21
Issue
20
Identifiers
DOI: 10.3390/ijms21207790
PMID: 33096780
PMCID: PMC7590139
Source
PubMed Central
Keywords
License
Green

Abstract

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases. Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumor aggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers. Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

Report this publication

Statistics

Seen <100 times